Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

PHASE4CompletedINTERVENTIONAL
Enrollment

861

Participants

Timeline

Start Date

August 10, 2015

Primary Completion Date

January 10, 2017

Study Completion Date

June 2, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

Copaxone®

Subcutaneous Injections

Trial Locations (97)

1010

Teva Investigational Site 33040, Vienna

1200

Teva Investigational Site 37066, Brussels

2650

Teva Investigational Site 37063, Edegem

3100

Teva Investigational Site 21098, Mexico City

6002

Teva Investigational Site 35205, Nice

10000

Teva Investigational Site 60034, Zagreb

Teva Investigational Site 60035, Zagreb

Teva Investigational Site 60036, Zagreb

Teva Investigational Site 60040, Zagreb

11042

Teva Investigational Site 13482, New Hyde Park

14050

Teva Investigational Site 21097, Mexico City

14269

Teva Investigational Site 21095, Mexico City

16132

Teva Investigational Site 30163, Genova

18147

Teva Investigational Site 32606, Rostock

20122

Teva Investigational Site 30165, Milan

20127

Teva Investigational Site 30164, Milan

20249

Teva Investigational Site 32602, Hamburg

20520

Teva Investigational Site 40015, Turku

23456

Teva Investigational Site 13480, Virginia Beach

25018

Teva Investigational Site 30161, Montichiari

25030

Teva Investigational Site 35211, Besançon

27607

Teva Investigational Site 13471, Raleigh

28006

Teva Investigational Site 31180, Madrid

29010

Teva Investigational Site 31177, Málaga

30029

Teva Investigational Site 35206, Nîmes

Teva Investigational Site 35212, Nîmes

30120

Teva Investigational Site 31179, El Palmar

30327

Teva Investigational Site 13478, Atlanta

31059

Teva Investigational Site 35209, Toulouse

33076

Teva Investigational Site 35203, Bordeaux

33100

Teva Investigational Site 40014, Tampere

34098

Teva Investigational Site 82051, Istanbul

34250

Teva Investigational Site 82049, Istanbul

35000

Teva Investigational Site 60039, Slavonski Brod

35033

Teva Investigational Site 35202, Rennes

41009

Teva Investigational Site 31182, Seville

41010

Teva Investigational Site 31184, Seville

41380

Teva Investigational Site 82050, Kocaeli

43214

Teva Investigational Site 13473, Columbus

44685

Teva Investigational Site 13477, Uniontown

46026

Teva Investigational Site 31178, Valencia

51000

Teva Investigational Site 60037, Rijeka

54035

Teva Investigational Site 35204, Nancy

55422

Teva Investigational Site 13479, Golden Valley

Teva Investigational Site 13483, Golden Valley

59000

Teva Investigational Site 35208, Lille

59160

Teva Investigational Site 35214, Lomme

60062

Teva Investigational Site 13475, Northbrook

63003

Teva Investigational Site 35210, Clermont-Ferrand

67091

Teva Investigational Site 35201, Strasbourg

69677

Teva Investigational Site 35207, Bron

70124

Teva Investigational Site 30169, Bari

70174

Teva Investigational Site 32604, Stuttgart

78303

Teva Investigational Site 35213, Poissy

78681

Teva Investigational Site 13481, Round Rock

80131

Teva Investigational Site 30167, Naples

89106

Teva Investigational Site 13487, Las Vegas

95445

Teva Investigational Site 32605, Bayreuth

95608

Teva Investigational Site 13524, Carmichael

125367

Teva Investigational Site 50387, Moscow

127015

Teva Investigational Site 50374, Moscow

150030

Teva Investigational Site 50378, Yaroslavl

194044

Teva Investigational Site 50377, Saint Petersburg

197110

Teva Investigational Site 50375, Saint Petersburg

248007

Teva Investigational Site 50392, Kaluga

420021

Teva Investigational Site 50390, Kazan'

603003

Teva Investigational Site 50373, Moscow

625048

Teva Investigational Site 50372, Tyumen

630007

Teva Investigational Site 50376, Novosibirsk

660049

Teva Investigational Site 50391, Krasnoyarsk

35058-1565

Teva Investigational Site 13485, Cullman

02035

Teva Investigational Site 13472, Foxborough

07666

Teva Investigational Site 13470, Teaneck

C1061ABD

Teva Investigational Site 20061, Buenos Aires

C1280AEB

Teva Investigational Site 20062, Buenos Aires

S2002KQJ

Teva Investigational Site 20063, Rosario

?01307

Teva Investigational Site 32603, Dresden

Unknown

Teva Investigational Site 44029, Dublin

Teva Investigational Site 50389, Perm

?00133

Teva Investigational Site 30166, Rome

?00152

Teva Investigational Site 30162, Rome

03310

Teva Investigational Site 21096, DF

85-795

Teva Investigational Site 53352, Bydgoszcz

80-803

Teva Investigational Site 53354, Gdansk

26-200

Teva Investigational Site 53353, Gmina Końskie

40-635

Teva Investigational Site 53350, Katowice

25-726

Teva Investigational Site 53349, Kielce

90-324

Teva Investigational Site 53356, Lodz

90-549

Teva Investigational Site 53348, Lodz

20-016

Teva Investigational Site 53345, Lublin

10-560

Teva Investigational Site 53355, Olsztyn

44-200

Teva Investigational Site 53351, Rybnik

35-055

Teva Investigational Site 53347, Rzeszów

?00-909

Teva Investigational Site 53346, Warsaw

00969

Teva Investigational Site 13476, Guaynabo

09006

Teva Investigational Site 31181, Burgos

?06100

Teva Investigational Site 82052, Ankara

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT02499900 - Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® | Biotech Hunter | Biotech Hunter